[HTML][HTML] Understanding and targeting prostate cancer cell heterogeneity and plasticity
DG Tang - Seminars in cancer biology, 2022 - Elsevier
Prostate cancer (PCa) is a prevalent malignancy that occurs primarily in old males. Prostate
tumors in different patients manifest significant inter-patient heterogeneity with respect to …
tumors in different patients manifest significant inter-patient heterogeneity with respect to …
Therapy considerations in neuroendocrine prostate cancer: what next?
H Beltran, F Demichelis - Endocrine-Related Cancer, 2021 - erc.bioscientifica.com
Lineage plasticity and histologic transformation to small cell neuroendocrine prostate cancer
(NEPC) is an increasingly recognized mechanism of treatment resistance in advanced …
(NEPC) is an increasingly recognized mechanism of treatment resistance in advanced …
The DNA methylation landscape of advanced prostate cancer
Although DNA methylation is a key regulator of gene expression, the comprehensive
methylation landscape of metastatic cancer has never been defined. Through whole …
methylation landscape of metastatic cancer has never been defined. Through whole …
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a …
Background The majority of patients with metastatic castration-resistant prostate cancer
(mCRPC) will have disease progression of a uniformly fatal disease. mCRPC is driven by …
(mCRPC) will have disease progression of a uniformly fatal disease. mCRPC is driven by …
MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets
Abstract c-MYC (MYC) is a major driver of prostate cancer tumorigenesis and progression.
Although MYC is overexpressed in both early and metastatic disease and associated with …
Although MYC is overexpressed in both early and metastatic disease and associated with …
Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer
The homologous recombination deficiency (HRD) score integrates three DNA-based
measures of genomic instability, and has been understudied in prostate cancer. Given the …
measures of genomic instability, and has been understudied in prostate cancer. Given the …
Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance
The androgen receptor (AR) antagonist enzalutamide is one of the principal treatments for
men with castration-resistant prostate cancer (CRPC). However, not all patients respond …
men with castration-resistant prostate cancer (CRPC). However, not all patients respond …
Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences
W Rayford, AT Beksac, J Alger, M Alshalalfa… - Communications …, 2021 - nature.com
Racial disparities in prostate cancer have not been well characterized on a genomic level.
Here we show the results of a multi-institutional retrospective analysis of 1,152 patients (596 …
Here we show the results of a multi-institutional retrospective analysis of 1,152 patients (596 …
A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
Resistance to next-generation anti-androgen enzalutamide (ENZ) constitutes a major
challenge for the treatment of castration-resistant prostate cancer (CRPC). By performing …
challenge for the treatment of castration-resistant prostate cancer (CRPC). By performing …
BET bromodomain inhibition blocks an AR-repressed, E2F1-activated treatment-emergent neuroendocrine prostate cancer lineage plasticity program
DH Kim, D Sun, WK Storck, K Welker Leng… - Clinical Cancer …, 2021 - AACR
Purpose: Lineage plasticity in prostate cancer—most commonly exemplified by loss of
androgen receptor (AR) signaling and a switch from a luminal to alternate differentiation …
androgen receptor (AR) signaling and a switch from a luminal to alternate differentiation …